EU approves 'Privacy Shield" Data-Transfer agreement with US
Following several months of uncertainty and speculation, the trans-Atlantic agreement between the European Union and the United States of America has been officially adopted on Tuesday the 12th of July, 2016.
RWANDA: Changes to IP Legislation
Past April 20th, 2016 the Rwandan government has released an Official Gazette Special.
This important document, drafted in Kinyarwanda, French and English, makes effective recently promulgated laws and modifies various IP laws. The main changes are the following:
Chelsea to Man. United: You can have the coach, but not his name
It is official, as from today, (27/05/16) José Mourinho is officially Manchester United’s new manager. An announcement such as this would normally call for a celebration for “sealing the deal”, but for the executives responsible for the transfer there is still unsettled issues that need to be pondered and addressed.
Xiaomi gains access to 1500 Microsoft smartphone related patents
Founded in 2010 by the entrepreneur Lei Jun, Xiaomi is one of China’s largest mobile brands, just recently announced a licensing deal of around 1,500 patents from the software-giant Microsoft. Pundits suggest this move is an effort to expand from China into western markets.
U.S: DuPont trade secrets thief goes to jail
The Department of Justice (USDOJ) in collaboration with the Federal Bureau of Investigation (FBI) has sentenced a former DuPont employee for his participation in the theft and transfer of trade secrets.
The American chemical company DuPont is known for the development of Kevlar which is the registered trademark for a synthetic fibre which is widely used for industrial, technological and military purposes.
World Health Assembly: Is a compulsory licensing a solution against the high price of medicines?
The Sixty-eighth session of the World Health Assembly (WHA) took place in Geneva 18–26 May 2015. One of the issues that have been addressed was the high prices of medicines in Europe. Actually this is a growing problem in the EU. In the past few years the price of the medicines have been increasing exceeding the ability of the patients to pay for it. It is enough to recall the recent case involving the drugs to treat hepatitis C (HCV) which have an unsustainable price when compared to previous generation treatments.